Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.

A delicate balance: the cost effectiveness of new antiplatelet agents. J Am Coll Cardiol (2015) 0.75

Coronary artery disease is associated with persistent lower quality of life in women. Open Heart (2015) 0.75

Health utility indexes in patients with acute coronary syndromes. Open Heart (2016) 0.75

Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial. JAMA Surg (2014) 1.61

Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol (2013) 1.51

Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in Sweden. Int J Health Policy Manag (2014) 1.17

Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol (2014) 0.85

Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). Am J Cardiol (2013) 0.81

Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). Am J Cardiol (2015) 0.80

Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am J Cardiol (2014) 0.80

Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention. J Am Coll Cardiol (2014) 0.77

Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol (2017) 0.76

Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation". Circulation (2014) 0.75

Including Both Costs and Effects--The Challenge of Using Cost-Effectiveness Data in National-Level Policy-Making: A Response to Recent Commentaries. Int J Health Policy Manag (2015) 0.75

Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). Am J Cardiol (2015) 0.75

Appropriate Use Criteria for Coronary Revascularization and the Learning Health System: A Good Start. JAMA (2015) 0.75

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value. JAMA Cardiol (2017) 0.75

European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes (2020) 0.75

Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc (2017) 0.75

Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J (2014) 0.75

PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability. JAMA (2017) 0.75

Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. J Am Heart Assoc (2017) 0.75

Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. JAMA Cardiol (2016) 0.75

Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA (2022) 0.75

Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program. Am Heart J (2017) 0.75

Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol (2017) 0.75

Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial. J Am Coll Cardiol (2017) 0.75